Sana Biotechnology, Inc. Class Action Lawsuit - SANA

The filed complaint alleges that Sana Biotechnology, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Sana was at significant risk of having insufficient funds to maintain its current operations and advance one or more of its product candidates; (ii) SC291 in oncology, SC379, and SG299 were less promising than defendants had led investors to believe; (iii) in order to preserve cash and advance its more promising product candidates, Sana was likely to decrease funding for and/or discontinue SC291 in oncology, SC379, and SG299, as well as significantly reduce its headcount; (iv) accordingly, defendants overstated Sana’s financial capacity to maintain its current operations and advance its existing product candidates; and (v) as a result, defendants’ public statements were materially false and/or misleading at all relevant times.

In order to be eligible to join the SANA class action lawsuit, you must have incurred a loss on shares of Sana Biotechnology, Inc. purchased during the class period listed above.

If you suffered a loss in Sana Biotechnology, Inc. during the relevant time frame or pursuant to the relevant offering(s), you have until May 20, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.